High Risk of Preventable and Mitigable Adverse Events in Cancer Care
Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable events.
Breast Cancer Survival Outcomes After Mastectomy vs Breast-Conserving Surgery
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery.
Genetic Testing Underutilized in Women With History of Ovarian Cancer
Less than 20% of patients with a history of ovarian cancer meeting NCCN guidelines have undergone genetic testing or have discussed testing with their health care providers.
Aggressive Local Therapy Improves Outcomes in Patients With Head, Neck Cancer
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma.
Resistance Mutations Predict Metastatic Patients in NSCLC
Specific gene rearrangements associated with increased resistance to standard therapy may predict different metastasis distributions in patients with non-small cell lung cancer.
Financial Burden of ACPA Status in Patients With Rheumatoid Arthritis
A recent comparative effectiveness study examined the relationship of anticitrullinated protein antibody status and accrued economic burden for patients with rheumatoid arthritis.
Comparative Effectiveness Study Evaluates Options for DLBCL
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma.
Pancreatic Cancer Guidelines Do Not Cover Some Targetable Mutations
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer.
Novel Prostate Cancer Biomarkers May Improve Targeted Therapy
Research uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts.
Standard of Care Breakthrough in Platinum-Sensitive Ovarian Cancer
Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in PFS with a specific maintenance therapy, regardless of their disease characterization.
